Amino-Terminal Pro-B-Type Natriuretic Peptide Testing for the Diagnosis or Exclusion of Heart Failure in Patients with Acute Symptoms

American Journal of Cardiology

Volumn 101, Issue 3 SUPPL., 2008, Pages

  Januzzi Jr , James L ^a   Chen Tournoux, Annabel A ^a   Moe, Gordon ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADVERSE OUTCOME; ALGORITHM; ARTICLE; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEART FAILURE; HUMAN; PHYSICAL EXAMINATION; PREDICTION; PRIORITY JOURNAL; RADIOLOGY; SENSITIVITY AND SPECIFICITY; SYMPTOM; VALIDATION STUDY;

ACUTE DISEASE; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; RECURRENCE; SENSITIVITY AND SPECIFICITY;

EID: 38649086157     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.11.017     Document Type: Article

References (59)

1. Arnold J.M., Liu P., Demers C., Dorian P., Giannetti N., Haddad H., Heckman G.A., Howlett J.G., Ignaszewski A., Johnstone D.E., et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 22 (2006) 23-45
2. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure), developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
3. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., Tavazzi L., Smiseth O.A., Gavazzi A., Haverich A., et al., Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 26 (2005) 1115-1140
4. Tang W.H., Francis G.S., Morrow D.A., Newby L.K., Cannon C.P., Jesse R.L., Storrow A.B., Christenson R.H., Apple F.S., Ravkilde J., and Wu A.H. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 116 (2007) e99-e109
5. Hammerer-Lercher A., Ludwig W., Falkensammer G., Muller S., Neubauer E., Puschendorf B., Pachinger O., and Mair J. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem 50 (2004) 1174-1183
6. Hammerer-Lercher A., Neubauer E., Muller S., Pachinger O., Puschendorf B., and Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 310 (2001) 193-197
7. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem 49 (2003) 976-979
8. Hunt P.J., Richards A.M., Nicholls M.G., Yandle T.G., Doughty R.N., and Espiner E.A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 47 (1997) 287-296
9. Lainchbury J.G., Campbell E., Frampton C.M., Yandle T.G., Nicholls M.G., and Richards A.M. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42 (2003) 728-735
10. Bayes-Genis A., Santalo-Bel M., Zapico-Muniz E., Lopez L., Cotes C., Bellido J., Leta R., Casan P., and Ordonez-Llanos J. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 6 (2004) 301-308
11. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 91 (2005) 606-612
12. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., Omland T., Storrow A.B., Abraham W.T., Wu A.H., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
13. Januzzi Jr. J.L., Camargo C.A., Anwaruddin S., Baggish A.L., Chen A.A., Krauser D.G., Tung R., Cameron R., Nagurney J.T., Chae C.U., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 (2005) 948-954
14. Anwaruddin S., Lloyd-Jones D.M., Baggish A., Chen A., Krauser D., Tung R., Chae C., and Januzzi Jr. J.L. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 47 (2006) 91-97
15. Tung R.H., Camargo Jr. C.A., Krauser D., Anwaruddin S., Baggish A., Chen A., and Januzzi Jr. J.L. Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med 48 (2006) 66-74
16. Moe G.W., Howlett J., Januzzi J.L., and Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 115 (2007) 3103-3110
17. Krauser D.G., Chen A.A., Tung R., Anwaruddin S., Baggish A.L., and Januzzi Jr. J.L. Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. J Card Fail 12 (2006) 452-457
18. Knudsen C.W., Clopton P., Westheim A., Klemsdal T.O., Wu A.H., Duc P., McCord J., Nowak R.M., Hollander J.E., Storrow A.B., et al. Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the Breathing Not Properly Multinational Study. Ann Emerg Med 45 (2005) 573-580
19. Januzzi J.L., van Kimmenade R., Lainchbury J., Bayes-Genis A., Ordonez-Llanos J., Santalo-Bel M., Pinto Y.M., and Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur Heart J 27 (2006) 330-337
20. Berdague P., Caffin P.Y., Barazer I., Vergnes C., Sedighian S., Letrillard S., Pilossof R., Goutorbe F., Piot C., and Reny J.L. Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. Am Heart J 151 (2006) 690-698
21. Baggish A.L., van Kimmenade R.R.J., and Januzzi Jr. J.L. Extending beyond heart failure: the differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. Am J Cardiol 101 (2008) 43A-48A
22. James S.K., Lindahl B., Siegbahn A., Stridsberg M., Venge P., Armstrong P., Barnathan E.S., Califf R., Topol E.J., Simoons M.L., and Wallentin L. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108 (2003) 275-281
23. Arat-Ozkan A., Kaya A., Yigit Z., Balci H., Okcun B., Yazicioglu N., and Kucukoglu S. Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis. Echocardiography 22 (2005) 473-478
24. Davutoglu V., Celik A., Aksoy M., Sezen Y., Soydinc S., and Gunay N. Plasma NT-proBNP is a potential marker of disease severity and correlates with symptoms in patients with chronic rheumatic valve disease. Eur J Heart Fail 7 (2005) 532-536
25. Iltumur K., Karabulut A., Yokus B., Yavuzkir M., Taskesen T., and Toprak N. N-terminal proBNP plasma levels correlate with severity of mitral stenosis. J Heart Valve Dis 14 (2005) 735-741
26. Sutton T.M., Stewart R.A., Gerber I.L., West T.M., Richards A.M., Yandle T.G., and Kerr A.J. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 41 (2003) 2280-2287
27. Weber M., Arnold R., Rau M., Brandt R., Berkovitsch A., Mitrovic V., and Hamm C. Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol 94 (2004) 740-745
28. Weber M., Arnold R., Rau M., Elsaesser A., Brandt R., Mitrovic V., and Hamm C. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 26 (2005) 1023-1030
29. Weber M., Hausen M., Arnold R., Nef H., Moellman H., Berkowitsch A., Elsaesser A., Brandt R., Mitrovic V., and Hamm C. Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 92 (2006) 1639-1644
30. Yusoff R., Clayton N., Keevil B., Morris J., and Ray S. Utility of plasma N-terminal brain natriuretic peptide as a marker of functional capacity in patients with chronic severe mitral regurgitation. Am J Cardiol 97 (2006) 1498-1501
31. Corell P., Gustafsson F., Kistorp C., Madsen L.H., Schou M., and Hildebrandt P. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure. Int J Cardiol 117 (2007) 395-402
32. Morello A., Lloyd-Jones D.M., Chae C.U., van Kimmenade R.R., Chen A.C., Baggish A.L., O'Donoghue M., Lee-Lewandrowski E., and Januzzi Jr. J.L. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J 153 (2007) 90-97
33. Rienstra M., Van Gelder I.C., Van den Berg M.P., Boomsma F., and Van Veldhuisen D.J. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. Europace 8 (2006) 482-487
34. Binder L., Pieske B., Olschewski M., Geibel A., Klostermann B., Reiner C., and Konstantinides S. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 112 (2005) 1573-1579
35. Kostrubiec M., Pruszczyk P., Kaczynska A., and Kucher N. Persistent NT-proBNP elevation in acute pulmonary embolism predicts early death. Clin Chim Acta 382 (2007) 124-128
36. Kucher N., Printzen G., Doernhoefer T., Windecker S., Meier B., and Hess O.M. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 107 (2003) 1576-1578
37. Brueckmann M., Huhle G., Lang S., Haase K.K., Bertsch T., Weiss C., Kaden J.J., Putensen C., Borggrefe M., and Hoffmann U. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 112 (2005) 527-534
38. Januzzi J.L., Morss A., Tung R., Pino R., Fifer M.A., Thompson B.T., and Lee-Lewandrowski E. Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. Crit Care 10 (2006) R37
39. Ekstein S., Nir A., Rein A.J., Perles Z., Bar-Oz B., Salpeter L., Algur N., and Weintraub M. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol 29 (2007) 440-444
40. Erkus B., Demirtas S., Yarpuzlu A.A., Can M., Genc Y., and Karaca L. Early prediction of anthracycline induced cardiotoxicity. Acta Paediatr 96 (2007) 506-509
41. Schou M., Gustafsson F., Nielsen P.H., Madsen L.H., Kjaer A., and Hildebrandt P.R. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 9 (2007) 68-74
42. Januzzi Jr. J.L., Sakhuja R., O'Donoghue M., Baggish A.L., Anwaruddin S., Chae C.U., Cameron R., Krauser D.G., Tung R., Camargo Jr. C.A., and Lloyd-Jones D.M. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 166 (2006) 315-320
43. van Kimmenade R.R., Pinto Y.M., Bayes-Genis A., Lainchbury J.G., Richards A.M., and Januzzi Jr. J.L. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol 98 (2006) 386-390
44. van Kimmenade R.R.J., Pinto Y.M., and Januzzi Jr. J.L. Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations. Am J Cardiol 101 (2008) 39A-42A
45. Krauser D.G., Lloyd-Jones D.M., Chae C.U., Cameron R., Anwaruddin S., Baggish A.L., Chen A., Tung R., and Januzzi Jr. J.L. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 149 (2005) 744-750
46. Baggish A.L., Siebert U., Lainchbury J.G., Cameron R., Anwaruddin S., Chen A., Krauser D.G., Tung R., Brown D.F., Richards A.M., and Januzzi Jr. J.L. A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J 151 (2006) 48-54
47. Baggish A., Cameron R., Anwaruddin S., Chen A., Krauser D., Tung R., and Januzzi J.L. A clinical and biochemical critical pathway for the evaluation of patients with suspected acute congestive heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) algorithm. Crit Pathways Cardiol 3 (2004) 171-176
48. Green S.M., Redmond P., Januzzi J.L., Aleryani S., Lee-Lewandrowski E., Sluss P., and Lewandrowski K.B. The impact of amino-terminal pro-brain natriuretic peptide testing on hospital length of stay and morbidity in patients with acute decompensated heart failure. Arch Pathol Lab Med 131 (2007) 473-476
49. Siebert U., Januzzi Jr. J.L., Beinfeld M.T., Cameron R., and Gazelle G.S. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 98 (2006) 800-805
50. Porcel J.M. The use of probrain natriuretic peptide in pleural fluid for the diagnosis of pleural effusions resulting from heart failure. Curr Opin Pulm Med 11 (2005) 329-333
51. Porcel J.M., Vives M., Cao G., Esquerda A., Rubio M., and Rivas M.C. Measurement of pro-brain natriuretic peptide in pleural fluid for the diagnosis of pleural effusions due to heart failure. Am J Med 116 (2004) 417-420
52. Gegenhuber A., Mueller T., Dieplinger B., Lenz K., Poelz W., and Haltmayer M. Plasma B-type natriuretic peptide in patients with pleural effusions: preliminary observations. Chest 128 (2005) 1003-1009
53. Melanson S.E., Laposata M., Camargo Jr. C.A., Chen A.A., Tung R., Krauser D., Anwaruddin S., Baggish A., Cameron R., Sluss P., et al. Combination of d-dimer and amino-terminal pro-B-type natriuretic peptide testing for the evaluation of dyspneic patients with and without acute pulmonary embolism. Arch Pathol Lab Med 130 (2006) 1326-1329
54. Chen A.A., Wood M.J., Krauser D.G., Baggish A.L., Tung R., Anwaruddin S., Picard M.H., and Januzzi J.L. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J 27 (2006) 839-845
55. Tschope C., Kasner M., Westermann D., Gaub R., Poller W.C., and Schultheiss H.P. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 26 (2005) 2277-2284
56. Tschope C., Kasner M., Westermann D., Walther T., Gaub R., Poller W.C., and Schultheiss H.P. Elevated NT-ProBNP levels in patients with increased left ventricular filling pressure during exercise despite preserved systolic function. J Card Fail 11 suppl (2005) S28-S33
57. O'Donoghue M., Chen A., Baggish A.L., Anwaruddin S., Krauser D.G., Tung R., and Januzzi J.L. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Card Fail 11 suppl (2005) S9-S14
58. Maisel A.S., McCord J., Nowak R.M., Hollander J.E., Wu A.H., Duc P., Omland T., Storrow A.B., Krishnaswamy P., Abraham W.T., et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 41 (2003) 2010-2017
59. Sakhuja R., Chen A.A., Anwaruddin S., Baggish A.L., and Januzzi Jr. J.L. Combined use of amino terminal-pro-brain natriuretic peptide levels and QRS duration to predict left ventricular systolic dysfunction in patients with dyspnea. Am J Cardiol 96 (2005) 263-266